News

Pharmabiz43m
AstraZeneca’s Imfinzi receives European approval to treat patients with resectable muscle-invasive bladder cancer
AstraZeneca’s Imfinzi receives European approval to treat patients with resectable muscle-invasive bladder cancer: Cambridge, UK Saturday, July 5, 2025, 09:00 Hrs [IST] AstraZen ...
Pharmabiz1h
ICMR-NIREH to host workshop on ddPCR from August 11 to 14 with special emphasis on molecular virology
Shardul Nautiyal, Mumbai Saturday, July 5, 2025, 08:00 Hrs [IST] ...
Pharmabiz1h
Pharma export continues its growth trajectory with USD 2,475.70 million in May 2025
The Pharmaceuticals Export Promotion Council of India (Pharmexcil) has reported that India's pharmaceutical export continued its growth trajectory with USD 2,475.70 million in May 2025, cumulating to ...
Pharmabiz1h
Indian healthcare sector grapples with acute shortages of infrastructure & skilled professionals: Dr Raj Nagarkar
Indian healthcare sector grapples with acute shortages of infrastructure & skilled professionals: Dr Raj Nagarkar: Nandita Vijayasimha, Bengaluru Saturday, July 5, 2025, 08:00 Hrs ...
Pharmabiz1h
Govt support fuels Indian pharma growth amidst challenges: T Revichandran
The Union government's substantial and commendable support for the Indian pharmaceutical industry, particularly for the MSME sector, is evident. T. Revichandran, vice-president of IDMA South Region, ...
Pharmabiz1h
DCC recommends DCGI to share SOPs and formats with States as per IDP
DCC recommends DCGI to share SOPs and formats with States as per IDP: Gireesh Babu, New Delhi Saturday, July 5, 2025, 08:00 Hrs [IST] The Drugs Consultative Committee (DCC) has re ...
Pharmabiz20h
Pharmac South 2025 opened at Chennai Trade Centre today
Our Bureau, Chennai Friday, July 4, 2025, 12:45 Hrs [IST] Pharmac South 2025, the 10th edition of South India's high-power ...
Pharmabiz16h
Lupin introduces ipratropium bromide nasal solution, 0.03% & 0.06% in US markets
Lupin introduces ipratropium bromide nasal solution, 0.03% & 0.06% in US markets: Our Bureau, Mumbai Friday, July 4, 2025, 17:30 Hrs [IST] Global pharma major Lupin Limited (Lupin ...
Pharmabiz15h
CytoDyn announces encouraging clinical findings among patients with advanced metastatic colorectal cancer previously treated with leronlimab
CytoDyn announces encouraging clinical findings among patients with advanced metastatic colorectal cancer previously treated with leronlimab: Vancouver, Washington Friday, July 4, ...
Pharmabiz16h
Jaslok Hospital performs first-of-its-kind lutetium therapy saving terminal prostate cancer patient
Jaslok Hospital performs first-of-its-kind lutetium therapy saving terminal prostate cancer patient: Our Bureau, Mumbai Friday, July 4, 2025, 17:15 Hrs [IST] In a first-of-its-kin ...
Pharmabiz16h
Nuravax, Institute for Molecular Medicine to present phase 1 results & phase 2 design of Alzheimer’s vaccine AV-1959R at CTAD 2025
Nuravax, Institute for Molecular Medicine to present phase 1 results & phase 2 design of Alzheimer’s vaccine AV-1959R at CTAD 2025: Irvine, California Friday, July 4, 2025, 17:0 ...
Pharmabiz18h
Inmagene enrolls first patient in ADAPTIVE phase 2b clinical trial of IMG-007
Inmagene enrolls first patient in ADAPTIVE phase 2b clinical trial of IMG-007: San Diego Friday, July 4, 2025, 15:00 Hrs [IST] Inmagene Biopharmaceuticals (Inmagene), a clinical-s ...